Lead Sponsor

Sanofi

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Main study:
•Participants with RA who were previously randomized in the sarilumab RA clinical program: e.g., the EFC11072 study, ACT11575 study, EFC10832 study, SFY13370, and EFC13752 study.
•Sub-study:
•Participants enrolled in the LTS11210 study who were receiving either sarilumab 200mg q2w PFS or sarilumab 150mg q2w PFS and who were able and willing to participate in this sub-study.
•Participants who had been enrolled in the main study for at least 24 weeks. Participants must sign a sub-study written informed consent prior to any sub-study related procedure.

•Main study:
•Participants with any adverse event (AE) led to permanent study drug discontinuation from a prior study.
•Participants with an abnormality(ies) or AEs that per investigator judgment would adversely affect participation of the participant in the study.
•The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.